Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotime-Nasdaq's best kept secret? -- Ignore unavailable to you. Want to Upgrade?

To: Jim Roof who wrote (795)	3/31/1998 12:44:00 PM
From: Stephen How	Respond to of 1432

<<In other words, the non-SS lower amounts of transfused products (platelets, RBC, etc) in the Hextend group resulted in a lower post-op platelet count -- a wash. >> I think this is an area of confusion. I view the post-op platelet count of Hextend patients (which is lower) as a positive in and of itself. This signifies to me that these patients were functioning just fine and clotting just fine without the need to boost the count via blood products ... Were arguing about unclear interpretations of the second-order effects of a non-SS result! Again, I'll try to go to the medical library this weekend. I think we need more expert insight into the non-dilutional coagulopathies (researchers also consider this a second-order effect!). Anyways, go BTIM! Steve